Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Covalon Technologies ( (TSE:COV) ) just unveiled an announcement.
Covalon Technologies plans to release its first-quarter fiscal 2026 results on February 25, 2026, before the market opens and will host a conference call and webcast the same morning to discuss the figures and take questions from participants. The company will also make a recording of the call and related financial documents available to investors online, underscoring its efforts to maintain transparency and engagement with shareholders as it advances its position in the medical technology sector.
The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.
Spark’s Take on TSE:COV Stock
According to Spark, TipRanks’ AI Analyst, TSE:COV is a Neutral.
The score is driven primarily by mixed financial performance: a strong, low-debt balance sheet is offset by steep revenue and free-cash-flow declines. Technicals add caution with a price below key moving averages and negative MACD, while valuation is only middling with a P/E around 24 and no dividend support.
To see Spark’s full report on TSE:COV stock, click here.
More about Covalon Technologies
Covalon Technologies Ltd. is a Canadian MedTech company focused on advanced wound care, vascular access, and surgical consumables aimed at improving patient outcomes. Its products are designed to enhance healing, reduce healthcare-associated infections, and protect skin integrity, and the company is listed on the TSX Venture Exchange and trades on the OTCQX Market.
Average Trading Volume: 13,805
Technical Sentiment Signal: Sell
Current Market Cap: C$44.19M
For detailed information about COV stock, go to TipRanks’ Stock Analysis page.